Previous 10 | Next 10 |
DiaMedica Therapeutics Inc. (DMAC) Q1 2019 Earnings Conference Call May 14, 2019, 08:00 AM ET Company Participants Rick Pauls - President & CEO Scott Kellen - CFO Conference Call Participants Alex Nowak - Craig-Hallum Capital Edward Marks - H.C. Wainwright Thomas Flat...
DiaMedica Therapeutics (NASDAQ: DMAC ): Q1 GAAP EPS of -$0.27 misses by $0.06 . More news on: DiaMedica Therapeutics Inc., Diamedica Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Phase Ib study of DM199 in Chronic Kidney Disease nearing full enrollment Completion of new cGMP manufacturing run of DM199 Conference call with management tomorrow, May 14, 2019 at 7am CT MINNEAPOLIS, May 13, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: D...
MINNEAPOLIS, May 06, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its first quarter 2019 financial results will be released after market close on Monday, May 13 th . DiaMedica’s management will host a live conference call on Tuesday, ...
MINNEAPOLIS, April 30, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, today announced that Dr Harry Alcorn, its Chief Medical Officer will be presenting “ CKD New Therapeutic Development: DM199 for Chronic Kidney Disease &...
Gainers: Regional Health Properties (NYSEMKT: RHE ) +183% . Moleculin Biotech (NASDAQ: MBRX ) +51% . The KeyW Holding (NASDAQ: KEYW ) +43% . Key Energy Services (NYSE: KEG ) +32% . Iconix Brand Group (NASDAQ: ICON ) +25% . Lantronix (NASDAQ: LTRX ) +15% . Denbury Resources (NYS...
I have been studying what effect uplisting has on the stock price of individual stocks. My first article concluded that a profit exceeding 25% was available in 65% of stocks that had uplisted during 2015 but that profit evaporated within the first year after uplisting. Only 10% of these same...
The following slide deck was published by DiaMedica Therapeutics Inc. in conjunction with this Read more ...
DiaMedica Therapeutics Inc. (DMAC) Q4 2018 Earnings Conference Call March 00, 2019 09:00 AM ET Company Participants Rick Pauls - President & CEO Scott Kellen - CFO Conference Call Participants Alex Nowak - Craig-Hallum Capital Presentation Operator Good day, lad...
DiaMedica Therapeutics (NASDAQ: DMAC ): FY GAAP EPS of -$0.74 beats by $0.09 . More news on: DiaMedica Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
DiaMedica Therapeutics Inc. Company Name:
DMAC Stock Symbol:
NASDAQ Market:
DiaMedica Therapeutics Inc. Website:
Company to Host Preeclampsia Key Opinion Leader Event July 29, 2024 at 10 AM Eastern / 9 AM Central White Paper: The Potential of DM199 to Treat Preeclampsia DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel trea...
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic disease, today announced the closing of its previously announced $11.8 million private placement to accredited investors. The Company sold approximatel...
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 73.0% to $0.4585 on volume of 640,087,036 shares Ocean Power Technologies Inc. (OPTT) rose 34.9% to $0.1812 on volume of 396,326,565 shares NVIDIA Corporation (NVDA) rose 0.2% to $1...